Indications and recommendations for use of Apelix-Piqray

Alpelisib (Alpelisib)-Piqray, is a small molecule kinase inhibitor targeting the PI3K pathway, specifically used to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer with PIK3CA mutations. This type of mutation is common in HR+/HER2- breast cancer patients. About 40% of patients have abnormal expression of the PIK3CA gene, which activates the PI3K/Akt/mTOR signaling pathway, allowing tumor cells to escape estrogen suppression and increase drug resistance, leading to the failure of traditional endocrine therapy. Apelvis is a precision therapeutic drug designed to target this mechanism. It can selectively inhibit the PI3Kα isoform and block signaling in this pathway from the source.

This drug is usually used in combination with fulvestrant (Fulvestrant) to enhance the anti-tumor effect. It is suitable for patients who have previously received endocrine therapy and whose disease has progressed, especially when PIK3CA mutations are detected, and the effect is more significant. Genetic testing to confirm PIK3CA mutation status is recommended before using apelvis, which is a critical step in the clinical treatment pathway.

Patients' blood sugar levels and skin reactions need to be closely monitored during treatment, as the drug may cause metabolic or immune-related adverse reactions such as hyperglycemia and rash. Patients with a history of diabetes or insulin resistance should undergo a thorough evaluation before use. In terms of dosage, it needs to be adjusted according to individual tolerance to take into account both efficacy and safety. Physicians should also remind patients to maintain a regular diet and manage their weight to reduce metabolic risks.

In short, the introduction of Apelix-Piqray represents a major advance in the precision treatment of PIK3CA-mutated breast cancer and brings new treatment hope to advanced patients. Its medication decisions are highly dependent on molecular diagnostic results, emphasizing the treatment concept of "different for each individual", which is an important embodiment of personalized medicine in modern oncology.

Reference materials:https://www.piqray.com/